Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Swedish Orphan Biovitrum AB ( (SE:SOBI) ) is now available.
Sobi has entered into a capped royalty purchase agreement with Apellis Pharmaceuticals, significantly reducing its ex-U.S. royalty obligations for Aspaveli in exchange for a $275 million upfront payment and potential milestone payments. This strategic move underscores Sobi’s commitment to advancing treatments for rare diseases, particularly C3G and IC-MPGN, and highlights the potential of Aspaveli to transform patient outcomes in these areas.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company focused on developing and delivering innovative treatments for rare diseases. With approximately 1,900 employees worldwide, Sobi operates across Europe, North America, the Middle East, Asia, and Australia, generating a revenue of SEK 26 billion in 2024. The company is listed on Nasdaq Stockholm.
Average Trading Volume: 354,659
Current Market Cap: SEK97.75B
For detailed information about SOBI stock, go to TipRanks’ Stock Analysis page.